Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 Feb;33(2):209-14.
doi: 10.1016/j.ejcts.2007.11.011. Epub 2008 Jan 3.

Propensity score analysis of early and late outcome after redo off-pump and on-pump coronary artery bypass grafting

Affiliations
Comparative Study

Propensity score analysis of early and late outcome after redo off-pump and on-pump coronary artery bypass grafting

Hunaid A Vohra et al. Eur J Cardiothorac Surg. 2008 Feb.

Abstract

Background: The purpose of this study was to compare early and late results of redo-CABG with (redo-ONCAB) and without (redo-OPCAB) cardiopulmonary bypass.

Methods: From April 2001 to September 2006 redo-CABG was performed in 110 patients (redo-ONCAB=50 and redo-OPCAB=60). Applying the propensity score, 43 OPCAB patients were matched with 43 ONCAB patients. The mean EuroScore was 5+/-4.7 and 5+/-3.4 for redo-ONCAB and redo-OPCAB, respectively (p=0.5). The number of diseased coronary arteries was 3+/-0.5 and 2+/-0.8 in redo-ONCAB and redo-OPCAB, respectively (p<0.01).

Results: Twelve patients underwent OPCAB through anterior thoracotomy while the rest of the patients (n=74) underwent median sternotomy. Mean number of grafts performed was 3+/-0.8 in redo-ONCAB and 2+/-0.6 in redo-OPCAB (p<0.05). The need for postoperative insertion of intra-aortic balloon pump (IABP) was higher (p=0.02) in redo-ONCAB (n=9, 21%) than redo-OPCAB (n=1, 2%). The duration of postoperative ventilation was 55+/-98.7 h for redo-ONCAB and 10+/-12.8h for redo-OPCAB (p=0.008). No differences were found in the incidence of other postoperative complications. The 30-day mortality rate was 6.9% for redo-ONCAB (n=3) and 2.3% redo-OPCAB (n=1; p=NS). Mean follow-up for redo-ONCAB was 30+/-21.3 months (range 0.1-63 months) and that of redo-OPCAB was 37+/-19.2 months (0.1-62.5 months). Actuarial survival at 5 years was 87+/-5.5% for redo-ONCAB and 95+/-3.2% for redo-OPCAB (p=0.17). Event-free survival was 71+/-8.0% for redo-ONCAB and 78+/-7.2% for redo-OPCAB (p=0.32).

Conclusion: OPCAB is an acceptable strategy in selected patients requiring redo-CABG. Employing a strategy of OPCAB for those patients with 2 or fewer lesions and ONCAB for those with more diffuse disease, redo-OPCAB and redo-ONCAB have similar early and late outcomes.

PubMed Disclaimer

Publication types